A MULTICOHORT PHASE 1B STUDY (STELLAR-002) OF XL092 IN COMBINATION WITH IMMUNOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Mcgregor, Bradley [1 ]
Choueiri, Toni [1 ]
Shah, Neil [2 ]
Bajaj, Aung [3 ]
Chahoud, Jad [4 ]
O'Neil, Bert [5 ]
Michalski, Joel [6 ]
Garmezy, Benjamin [7 ]
Jin, Lixian [8 ]
Aziz, Usman [9 ]
Xu, Fiona [9 ]
Motzer, Robert [2 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Arizona Oncol, Tucson, AZ USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Indiana Univ, Indianapolis, IN USA
[6] Nebraska Canc Specialists, Omaha, NE USA
[7] Sarah Cannon Res Inst, Nashville, TN USA
[8] Bristol Myers Squibb, Lawrenceville, NY USA
[9] Exelixis Inc, Alameda, CA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0742
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
742
引用
收藏
页码：A775 / A775
页数：1
相关论文
共 50 条
  • [1] A phase 1b study (STELLAR-002) of XL092 administered in combination with nivolumab (NIVO) with or without ipilimumab (IPI) or bempegaldesleukin (BEMPEG) in patients (pts) with advanced solid tumors
    Choueiri, Toni K.
    McGregor, Bradley Alexander
    Shah, Neil J.
    Bajaj, Aung
    Chahoud, Jad
    O'Neil, Bert
    Michalski, Joel
    Garmezy, Benjamin
    Jin, Lixian
    Oliver, Jennifer Wright
    Wang, Yijia
    Tayama, Darren
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab
    Sharma, M. R.
    Subbiah, V.
    Shapiro, G.
    Pal, S. K.
    Agarwal, N.
    Wentzel, K.
    Fang, B.
    Zhang, N.
    Schwickart, M.
    Wang, Z.
    Curran, D.
    Patnaik, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S760 - S760
  • [3] TRIAL IN PROGRESS: PHASE 1 FIRST-IN-HUMAN STUDY OF XL092 ADMINISTERED ALONE OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
    Patnaik, Amita
    Subbiah, Vivek
    Shapiro, Geoffrey
    Pal, Sumanta
    Agarwal, Neeraj
    Wentzel, Kristopher
    Li, Jing
    McIlvaine, Elizabeth
    Waldes, Jana
    Cha, Edward
    Tadjalli-Mehr, Keyvan
    Sharma, Manish
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A544 - A544
  • [4] A phase 1b/2 study of ramucirumab in combination with emibetuzumab in patients with advanced solid tumors
    Bendell, Johanna
    Fuchs, Charles
    Voss, Martin
    Bauer, Todd M.
    Choueiri, Toni K.
    Drilon, Alexander
    Thorn, Katharine
    Wijayawardana, Sameera
    Moser, Brian
    Urunuela, Arantxa
    Wacheck, Volker
    Harding, James J.
    CANCER RESEARCH, 2017, 77
  • [5] STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer
    Hecht, J. Randolph
    Tabernero, Josep
    Raj Parikh, Aparna
    Wang, Yijia
    Wang, Zhong
    Schwickart, Martin
    Curran, Dominic
    Saeed, Anwaar
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors
    Paluri, Ravi
    Madan, Ankit
    Li, Peng
    Jones, Benjamin
    Saleh, Mansoor
    Jerome, Mary
    Miley, Deborah
    Keef, Jennifer
    Robert, Francisco
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (03) : 551 - 559
  • [7] Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors
    Ravi Paluri
    Ankit Madan
    Peng Li
    Benjamin Jones
    Mansoor Saleh
    Mary Jerome
    Deborah Miley
    Jennifer Keef
    Francisco Robert
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 551 - 559
  • [8] STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).
    Hecht, J. Randolph
    Tabernero, Josep
    Parikh, Aparna Raj
    Wang, Yijia
    Wang, Zhong
    Schwickart, Martin
    Curran, Dominic
    Saeed, Anwaar
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS267 - TPS267
  • [9] Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
    Paluri, Ravi Kumar
    Li, Peng
    Jones, Benjamin Scott
    Madan, Ankit
    Jerome, Mary
    Miley, Debi
    Keef, Jennifer
    Robert, Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
    Weekes, Colin
    Lockhart, A. Craig
    Lee, James J.
    Sturm, Isrid
    Cleton, Adriaan
    Huang, Funan
    Lenz, Heinz-Josef
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (09) : 2450 - 2458
12345